In a major boost to India’s digital health landscape, Eli Lilly and Company has inaugurated a 2,20,000 square-foot global digital innovation hub in Hyderabad. The facility is located in the Phoenix Equinox campus in Gachibowli. It aims to accelerate drug development by integrating AI, cloud computing, automation, and advanced analytics into Lilly’s global research and development (R&D) operations.
A Milestone Investment in India’s Tech and Life Sciences Ecosystem
The centre marks Lilly’s largest global technology investment to date and signals a renewed commitment to India’s role in global pharmaceutical innovation. Currently home to around 100 professionals, the site will scale up to 1,500 tech specialists by 2026. These experts will work on next-gen solutions such as AI-enabled drug discovery, real-time clinical data analysis, and digital therapeutics.
Diogo Rau, Lilly’s Chief Information & Digital Officer, stated, “This innovation centre will fast-track our R&D across the globe by combining Indian tech expertise with our scientific vision.”
Hyderabad Cements Its Position as a Digital Health Powerhouse
The launch reinforces Hyderabad’s status as a magnet for digital health investments. The move aligns with the Telangana government’s broader strategy to attract multinational life sciences firms. Its Genome Valley and Life Sciences Hub already house global players like Novartis and Sanofi.
Supporting National Goals in Pharma Innovation and Digital Health
Lilly’s Hyderabad hub is well-positioned to support the government’s Pharma Vision 2025 and the National Digital Health Mission (NDHM). By integrating digital tools across the pharma value chain, the facility will enable:
*Real-time drug safety tracking
*Faster and smarter clinical trials
*Stronger post-market surveillance
The initiative also supports India’s ambition to become a preferred destination for global drug trials and medical R&D. It aligns with regulatory frameworks set by CDSCO and ICMR.
A New Era for Global Pharma, Powered by India
Once fully operational, the Hyderabad digital innovation hub will serve as a global nerve centre for Lilly’s R&D efforts — particularly in oncology, immunology, and chronic disease treatment. As reported by medicarepharmabusiness.com, Lilly’s investment reaffirms India’s dual status as not just the “pharmacy of the world”, but also an emerging leader in digital pharmaceutical innovation. Through this initiative, the country is poised to play a transformative role in shaping the future of global healthcare.
